AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation. Source: BioSpace

Ardelyx will receive a $30 million upfront payment and is eligible to receive additional development and commercialization milestones worth up to $130 million. Source: BioSpace

Kenneth Pittman, writing for Seeking Alpha, takes a look at why Shire is thinking of unloading its neuroscience division and suggesting an alternative. Source: BioSpace

The deal aims to accelerate local development of innovative medicines for patients in China and builds on AstraZeneca’s strong presence in the country. Source: BioSpace

While lirilumab was shown to be well-tolerated, it did not demonstrate efficacy in treating that patient population. Source: BioSpace

News of the layoffs comes hard on the heels of the company's credit rating having been cut to junk status by Fitch Rating. Source: BioSpace

Since taking over at Teva earlier this fall, Kare Schultz has been swiftly moving to shore up the finances and pay down the massive debts of the beleaguered pharmaceutical company.…

Biogen will receive an exclusive, worldwide license to commercialize ALKS 8700 and will pay Alkermes a mid-teens royalty on worldwide net sales of ALKS 8700. Source: BioSpace

The financing will be used to push its Phase III clinical program of MDR-101 in living donor HLA-matched kidney transplant patients. Source: BioSpace

Qiagen's investment will be an expansion of its current operations in that northern England city. Source: BioSpace